Skip to main content

Pemitinib 13.5 mg ( Pemigatinib)

Introduction to the Pemitinib Manufacturer

Pemitinib is identified as a product containing pemigatinib 13.5 mg, an oral targeted anticancer medicine belonging to the fibroblast growth factor receptor inhibitor class.

Understanding pharmaceutical manufacturing information is important when evaluating a prescription medicine. Manufacturer identity, product ownership, marketing authorization and distribution responsibilities help establish where a product comes from and which organizations are responsible for its pharmaceutical supply.

The specific manufacturer of Pemitinib has not been independently established from the product information available for this website. Therefore, no company should be identified as its manufacturer without supporting product documentation.

This page explains the relationship between pemigatinib, its established reference brand and the different companies that may participate in pharmaceutical manufacturing and distribution.

Who Developed Pemigatinib?

Incyte is the pharmaceutical company associated with the development of pemigatinib and its established reference brand, PEMAZYRE.

Pemigatinib was developed as a targeted therapy to inhibit selected fibroblast growth factor receptors.

Its development was based on scientific evidence showing that abnormal FGFR signaling can contribute to the growth and survival of certain cancer cells.

The medicine became an important treatment option for selected patients with FGFR2-altered cholangiocarcinoma and FGFR1-rearranged myeloid/lymphoid neoplasms under applicable regulatory labeling.

PEMAZYRE received its initial U.S. approval in 2020.

Understanding the Reference Product

PEMAZYRE is an established branded medicine containing pemigatinib.

The reference product is available in oral tablet strengths of:

  • 4.5 mg.
  • 9 mg.
  • 13.5 mg.

These strengths allow healthcare professionals to prescribe different doses and modify treatment when necessary.

The reference product’s regulatory authorization and product information are separate from the manufacturer and regulatory details of Pemitinib.

In the European Union, the marketing authorization holder for PEMAZYRE is Incyte Biosciences Distribution B.V.

Difference Between Developer and Manufacturer

A pharmaceutical developer is responsible for developing a medicine or its active ingredient.

A manufacturer is responsible for producing a specific pharmaceutical product.

These responsibilities may belong to different organizations.

For example, a company may discover and develop an active pharmaceutical ingredient, while another company manufactures a finished tablet containing that ingredient.

The distinction is important because a brand name alone does not establish the physical manufacturing company.

Brand Owner

A brand owner is the legal entity that owns or controls a commercial pharmaceutical brand.

The brand owner may be responsible for product presentation, commercial arrangements and brand management.

The specific legal brand ownership of Pemitinib should be confirmed using appropriate product and company documentation.

Marketing Authorization Holder

A marketing authorization holder is the organization legally responsible for a medicinal product’s authorization in a particular country or regulatory region.

This entity may have responsibilities involving regulatory submissions, product information, safety reporting and compliance with applicable requirements.

The marketing authorization holder may differ from the physical manufacturer.

Distributor and Supplier

A pharmaceutical distributor participates in the movement of medicines through the supply chain.

A supplier may arrange the provision of a product to a pharmacy, hospital, medical institution or another authorized buyer.

Neither role automatically establishes that the organization manufactures the medicine.

Why Manufacturer Identification Matters

Correct manufacturer information helps support product traceability and pharmaceutical transparency.

Important product details include:

  • Product name.
  • Generic medicine.
  • Strength.
  • Dosage form.
  • Manufacturer’s legal name.
  • Manufacturing address.
  • Marketing authorization holder.
  • Batch or lot number.
  • Manufacturing date.
  • Expiry date.
  • Country-specific registration information.
  • Package leaflet.
  • Packaging integrity.

These details should be consistent with official product documentation.

Product Quality Considerations

Pharmaceutical quality depends on appropriate manufacturing processes, quality-control testing and product stability.

For an oral pemigatinib tablet, relevant quality considerations include active ingredient identity, strength consistency, tablet formulation, impurities, dissolution characteristics and packaging stability.

The manufacturer’s quality systems should comply with applicable pharmaceutical manufacturing requirements.

However, specific manufacturing-site details, GMP certifications or quality certificates for Pemitinib should not be claimed without verification.

Pemitinib Manufacturer Information

Product DetailInformation
BrandPemitinib
Generic medicinePemigatinib
Strength13.5 mg
Drug classFGFR inhibitor
Reference brandPEMAZYRE
Reference product developerIncyte
Pemitinib manufacturer–
Brand owner–
Marketing authorization holder–

Conclusion

Pemigatinib is associated with Incyte through the development of the established reference product PEMAZYRE.

However, the specific manufacturer of Pemitinib 13.5 mg must be confirmed independently.

Accurate manufacturer identification is an important part of responsible pharmaceutical communication and product verification.